Vercirnon (GSK-1605786) sodium is a selective, orally active CCR9 antagonist; it inhibits CCR9-mediated Ca²⁺ mobilization and chemotaxis in Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively; it shows high selectivity for CCR9 over CCR1–12 and CX3CR1–7 (IC₅₀ > 10 µM); it is an equipotent inhibitor of CCL25-directed chemotaxis mediated by both CCR9 splice variants, CCR9A and CCR9B, with IC₅₀ values of 2.8 and 2.6 nM, respectively.